HRP20130042T1 - Postupci lijeäśenja reumatoidnog artritisa - Google Patents

Postupci lijeäśenja reumatoidnog artritisa Download PDF

Info

Publication number
HRP20130042T1
HRP20130042T1 HRP20130042AT HRP20130042T HRP20130042T1 HR P20130042 T1 HRP20130042 T1 HR P20130042T1 HR P20130042A T HRP20130042A T HR P20130042AT HR P20130042 T HRP20130042 T HR P20130042T HR P20130042 T1 HRP20130042 T1 HR P20130042T1
Authority
HR
Croatia
Prior art keywords
antibody
fragment
dose
use according
pharmaceutical composition
Prior art date
Application number
HRP20130042AT
Other languages
English (en)
Croatian (hr)
Inventor
Alan M. Solinger
Alexander Owyang
Original Assignee
Xoma Technology Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xoma Technology Ltd. filed Critical Xoma Technology Ltd.
Publication of HRP20130042T1 publication Critical patent/HRP20130042T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HRP20130042AT 2008-06-06 2009-06-05 Postupci lijeäśenja reumatoidnog artritisa HRP20130042T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5971108P 2008-06-06 2008-06-06
US9523208P 2008-09-08 2008-09-08
PCT/US2009/046441 WO2009149370A1 (en) 2008-06-06 2009-06-05 Methods for the treatment of rheumatoid arthritis

Publications (1)

Publication Number Publication Date
HRP20130042T1 true HRP20130042T1 (hr) 2013-03-31

Family

ID=40983388

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20130042AT HRP20130042T1 (hr) 2008-06-06 2009-06-05 Postupci lijeäśenja reumatoidnog artritisa

Country Status (12)

Country Link
US (1) US20110189172A1 (cg-RX-API-DMAC7.html)
EP (1) EP2293816B1 (cg-RX-API-DMAC7.html)
JP (2) JP5607613B2 (cg-RX-API-DMAC7.html)
AU (1) AU2009256072B2 (cg-RX-API-DMAC7.html)
CA (1) CA2727171A1 (cg-RX-API-DMAC7.html)
CY (1) CY1113640T1 (cg-RX-API-DMAC7.html)
DK (1) DK2293816T3 (cg-RX-API-DMAC7.html)
ES (1) ES2398693T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20130042T1 (cg-RX-API-DMAC7.html)
PL (1) PL2293816T3 (cg-RX-API-DMAC7.html)
PT (1) PT2293816E (cg-RX-API-DMAC7.html)
WO (1) WO2009149370A1 (cg-RX-API-DMAC7.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8034014B2 (en) 2007-03-06 2011-10-11 Biomet Biologics, Llc Angiogenesis initation and growth
US20080269762A1 (en) * 2007-04-25 2008-10-30 Biomet Manufacturing Corp. Method and device for repair of cartilage defects
CA2710252C (en) 2007-12-20 2017-03-28 Xoma Technology Ltd. Methods for the treatment of gout
US8753690B2 (en) 2008-02-27 2014-06-17 Biomet Biologics, Llc Methods and compositions for delivering interleukin-1 receptor antagonist
PL2259774T3 (pl) 2008-02-27 2013-04-30 Biomet Biologics Llc Sposoby i kompozycje dla wprowadzania antagonisty receptora interleukiny-1
US20110052561A1 (en) * 2009-08-27 2011-03-03 Biomet Biologics,LLC Osteolysis treatment
CN102573790B (zh) 2009-08-27 2017-03-22 拜欧米特生物制剂有限责任公司 用于产生白介素‑1受体拮抗剂的可植入装置
AU2011296356B2 (en) 2010-09-03 2015-07-09 Biomet Biologics, Llc Methods and compositions for delivering interleukin-1 receptor antagonist
RU2013115927A (ru) 2010-09-10 2014-10-20 Апексиджен, Инк. АНТИТЕЛА ПРОТИВ ИЛ-1β И СПОСОБЫ ПРИМЕНЕНИЯ
US9011846B2 (en) 2011-05-02 2015-04-21 Biomet Biologics, Llc Thrombin isolated from blood and blood fractions
US9573997B2 (en) * 2012-03-19 2017-02-21 Inserm (Institut National De La Sante Et De La Recherche Medicale) Method for use in the treatment of aneurysm
EP3750917A1 (en) 2012-11-05 2020-12-16 Delenex Therapeutics AG Binding members to il-1 beta
ES2895848T3 (es) 2012-12-17 2022-02-22 Cell Medica Inc Anticuerpos contra IL-1 beta
US20140271589A1 (en) 2013-03-15 2014-09-18 Biomet Biologics, Llc Treatment of collagen defects using protein solutions
US10143725B2 (en) 2013-03-15 2018-12-04 Biomet Biologics, Llc Treatment of pain using protein solutions
US9950035B2 (en) 2013-03-15 2018-04-24 Biomet Biologics, Llc Methods and non-immunogenic compositions for treating inflammatory disorders
US9758806B2 (en) 2013-03-15 2017-09-12 Biomet Biologics, Llc Acellular compositions for treating inflammatory disorders
US10208095B2 (en) 2013-03-15 2019-02-19 Biomet Manufacturing, Llc Methods for making cytokine compositions from tissues using non-centrifugal methods
US9895418B2 (en) 2013-03-15 2018-02-20 Biomet Biologics, Llc Treatment of peripheral vascular disease using protein solutions
US9878011B2 (en) 2013-03-15 2018-01-30 Biomet Biologics, Llc Treatment of inflammatory respiratory disease using biological solutions
WO2015081253A1 (en) 2013-11-26 2015-06-04 Biomet Biologics, Llc Methods of mediating macrophage phenotypes
SG11201703458UA (en) 2014-11-10 2017-05-30 Hoffmann La Roche Anti-ang2 antibodies and methods of use
KR20170080584A (ko) 2014-11-10 2017-07-10 에프. 호프만-라 로슈 아게 이중특이적 항체 및 안과학에서 이의 사용 방법
US10441635B2 (en) 2014-11-10 2019-10-15 Biomet Biologics, Llc Methods of treating pain using protein solutions
US9763800B2 (en) 2015-03-18 2017-09-19 Biomet C. V. Implant configured for hammertoe and small bone fixation
CN113444177A (zh) * 2020-03-27 2021-09-28 中山康方生物医药有限公司 抗IL-1β的抗体、其药物组合物及其用途
CN115281149A (zh) * 2021-05-12 2022-11-04 四川大学华西医院 一种临床前类风湿关节炎(Pre-RA)小鼠模型

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5077219A (en) * 1984-05-18 1991-12-31 New England Medical Center Hospitals Human IL-1 cDNA sequences encoding biologically-active human IL-1 proteins
EP0569687B1 (en) * 1984-05-18 2002-08-21 New England Medical Center Hospitals, Inc. Human IL-1 cDNA sequences encoding biologically-active human IL-1 proteins
US4762914A (en) * 1984-05-18 1988-08-09 Auron Philip E Truncated protein of interleukin-1
US5484887A (en) * 1984-06-19 1996-01-16 Immunex Corporation Homogeneous interleukin 1
US5122459A (en) * 1984-12-31 1992-06-16 Immunex Corporation Gene encoding biologically active human interleukin 1
US4772685A (en) * 1985-10-02 1988-09-20 Merck & Co., Inc. Immunogenic peptides of human interleukin-1 and the corresponding anti-peptide antibodies
US4935343A (en) * 1986-08-08 1990-06-19 Syntex (U.S.A.) Inc. Monoclonal antibodies for interleukin-1β
US5474899A (en) * 1987-05-13 1995-12-12 Cistron Biotechnology, Inc. Selective immunoassay for IL-1 β
DE68925935T2 (de) * 1988-10-01 1996-08-14 Otsuka Pharma Co Ltd Antikörper gegen Interleukin-1-beta
ES2113856T3 (es) * 1989-02-27 1998-05-16 New England Medical Center Inc Inhibidores de actividad biologica de il-1.
IE922437A1 (en) * 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
DE69233745D1 (de) * 1991-12-02 2008-10-23 Cambridge Antibody Tech Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken
US5869619A (en) * 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
EP1291360A1 (en) * 1991-12-13 2003-03-12 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
WO1994000470A1 (en) * 1992-06-30 1994-01-06 The Wistar Institute Of Anatomy And Biology DEVELOPMENTAL EMBRYONIC MOUSE cDNA LIBRARIES
US5959085A (en) * 1993-11-23 1999-09-28 Schering Corporation Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
US5817476A (en) * 1995-06-07 1998-10-06 Genetics Institute, Inc. Polynucleotides encoding interleukin-1 receptor intracellular ligand proteins
GB0001448D0 (en) * 2000-01-21 2000-03-08 Novartis Ag Organic compounds
AU2001259758A1 (en) * 2000-05-12 2001-11-26 Immunex Corporation Interleukin-1 inhibitors in the treatment of diseases
GB0020685D0 (en) * 2000-08-22 2000-10-11 Novartis Ag Organic compounds
US20030026806A1 (en) * 2000-10-27 2003-02-06 Amgen Inc. Antibodies and other selective IL-1 binding agents that allow binding to IL-1 receptor but not activation thereof
US20030166069A1 (en) * 2000-11-28 2003-09-04 Amgen, Inc. Interleukin-1 receptor antagonist-like molecules and uses thereof
US6727234B2 (en) * 2001-04-03 2004-04-27 University Of Iowa Research Foundation Isoprenoid analog compounds and methods of making and use thereof
EP1423432A4 (en) * 2001-07-26 2006-01-11 Lilly Co Eli ANTIBODIES TO INTERLEUKIN 1 BETA (IL-1BETA)
US20050152850A1 (en) * 2004-01-09 2005-07-14 Engebretson Steven P. Methods and compositions for facilitating metabolic control
US7732478B2 (en) * 2004-01-09 2010-06-08 The Trustees Of Columbia University In The City Of New York Methods for facilitating metabolic control
US8618054B2 (en) * 2004-05-05 2013-12-31 Valorisation-Rechereche Société en Commandite Interleukin-1 receptor antagonists, compositions, and methods of treatment
ES2335232T3 (es) * 2005-06-21 2010-03-23 Xoma Technology Ltd. Anticuerpos y fragmentos de los mismos que se unen a la il-1 beta.
WO2007050607A2 (en) * 2005-10-26 2007-05-03 Novartis Ag Novel use of il-1beta compounds
JP5645409B2 (ja) * 2006-12-20 2014-12-24 ゾーマ （ユーエス） リミテッド ライアビリティ カンパニー ＩＬ−１β関連疾患の治療方法
CA2710252C (en) * 2007-12-20 2017-03-28 Xoma Technology Ltd. Methods for the treatment of gout

Also Published As

Publication number Publication date
PT2293816E (pt) 2013-02-13
AU2009256072B2 (en) 2015-05-28
JP5809338B2 (ja) 2015-11-10
WO2009149370A1 (en) 2009-12-10
US20110189172A1 (en) 2011-08-04
JP2015007098A (ja) 2015-01-15
ES2398693T3 (es) 2013-03-21
JP5607613B2 (ja) 2014-10-15
JP2011522832A (ja) 2011-08-04
DK2293816T3 (da) 2013-02-04
AU2009256072A1 (en) 2009-12-10
EP2293816A1 (en) 2011-03-16
CY1113640T1 (el) 2016-06-22
EP2293816B1 (en) 2012-11-07
CA2727171A1 (en) 2009-12-10
PL2293816T3 (pl) 2013-04-30

Similar Documents

Publication Publication Date Title
HRP20130042T1 (hr) Postupci lijeäśenja reumatoidnog artritisa
EP2433650A3 (en) Administration of anti-CD3 antibodies in the treatment of autoimmune diseases
JP2015007098A5 (cg-RX-API-DMAC7.html)
BG108514A (en) METHODS OF ADMINISTERING ANTI-TNFalpha ANTIBODIES
JP2011507891A5 (cg-RX-API-DMAC7.html)
IL252631B1 (en) ACTIVIN-ACTRII antagonists and uses for the treatment of anemia
RU2017107559A (ru) Лечение раковых заболеваний с применением анти-nkg2a средств
RU2018100129A (ru) Способы лечения подагры
RU2011144312A (ru) БИСПЕЦИФИЧЕСКИЕ АНТИ-ErbB-3/АНТИ-С-МЕТ АНТИТЕЛА
WO2007147090A3 (en) Methods for the treatment of autoimmune disorders using monoclonal antibodies with reduced toxicity
EA200801165A1 (ru) Антагонисты неосновного рецептора-1 меланинконцентрирующего гормона
BR0209689A (pt) Uso de fragmento de hmg como agente anti-inflamatório
MXPA05007823A (es) Composicion y tratamiento de enfermedades desmielizantes y paralisis por administracion de agentes remielinizantes.
RU2015114923A (ru) СПОСОБЫ ЛЕЧЕНИЯ IL-1β-ЗАВИСИМЫХ ЗАБОЛЕВАНИЙ
JP2009518441A5 (cg-RX-API-DMAC7.html)
ME03797B (me) Stabilne formulacije koje sadrže anti-pcsk9 antitela
JP2014515763A5 (cg-RX-API-DMAC7.html)
SI2625199T1 (en) Procedures for treating psoriasis using IL-17 antagonists
BRPI0413394A (pt) formulação de lantánio mastigável em tablete, formulação farmacêutica em tablete ou em pó, método para tratar hiperfosfatemia, uso de uma quantidade terapeuticamente efetiva de uma formulação de um composto de lantánio, processo para preparar uma formulação em tablete de um composto de lantánio
JP2011522832A5 (cg-RX-API-DMAC7.html)
RU2015104001A (ru) Комбинированная терапия для лечения глиобластомы
JP2005506331A5 (cg-RX-API-DMAC7.html)
HRP20250113T1 (hr) Režim doziranja za gp100-specifični tcr - anti-cd3 scfv fuzijski protein
NZ542866A (en) Compositions and methods for the therapy of inflammatory bowel disease
EA201290172A1 (ru) Стабильные полипептиды, вариабельные домены антитела и антагонисты против tnfr1